Rekodi ya ushahidi wa mbinu

Bioequivalence Analysis

Bioequivalence Analysis is a regulatory-grade statistical framework used to determine whether a test drug formulation (generic or reformulated) delivers the active ingredient to the systemic circulation at a rate and extent comparable to a reference product. Introduced by Donald J. Schuirmann in 1987, the method operationalizes equivalence through the Two One-Sided Tests (TOST) procedure, replacing the ambiguous absence-of-difference paradigm with an explicit equivalence margin evaluated on log-transformed pharmacokinetic endpoints such as AUC and C_max.

Sources recorded, not reviewed

Rekodi ya chanzo

Nukuu zimehamishwa kwa uhalisi kutoka kwa rekodi ya chanzo cha mbinu. Hakuna uthibitisho wa kiwango cha dai unaodokezwa kutoka kwao.

Bioequivalence Analysis (Two One-Sided Tests)

Rekodi ya mbinu ya kiajenda · hypothesis-test / pharmacometrics

Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. · DOI 10.1007/BF01068419

Fungua mbinu kamili

Madai yaliyotunzwa

Madai yamehifadhiwa katika daftari la ushahidi, kila moja ikiwa na tathmini yake.

Hakuna madai yaliyotunzwa bado

Mwonekano huu haubuni tathmini ya dai wakati daftari haina yoyote.

Mbinu zinazohusiana

Zilizotengenezwa kutoka kwa grafu ya mbinu na kuonyeshwa kama uhusiano uliopendekezwa na mashine — hakuna dai la ushahidi linalodokezwa.

Same method familyEquivalence Test (TOST)machine-suggested · Relational suggestion, not evidence.Used in the same domainPharmacokinetic Compartment Modelmachine-suggested · Relational suggestion, not evidence.